诊断学理论与实践 ›› 2022, Vol. 21 ›› Issue (05): 638-643.doi: 10.16150/j.1671-2870.2022.05.017
收稿日期:
2021-12-15
出版日期:
2022-10-25
发布日期:
2023-01-29
通讯作者:
潘萌
E-mail:pm10633@rjh.com.cn
基金资助:
WANG Qijun, ZHU Haiqin, PAN Meng()
Received:
2021-12-15
Online:
2022-10-25
Published:
2023-01-29
Contact:
PAN Meng
E-mail:pm10633@rjh.com.cn
摘要:
天疱疮是一种严重的自身免疫性疾病,主要损害皮肤及黏膜的屏障功能。该病是由患者体内产生的针对细胞间黏附分子等结构的自身抗体导致,其中主要产生致病作用的抗体是针对桥粒芯蛋白(desmogelin,Dsg)1和Dsg3的抗体。这2种抗体主要通过空间位阻效应及抗原抗体结合之后的信号转导两方面机制致病,而抗Dsc抗体、抗斑蛋白家族抗体、抗乙酰胆碱受体抗体等也在致病过程中起着重要的协同作用。随着免疫荧光、酶联免疫吸附试验(enzyme-linked immunosorbent assays,ELISA)等技术的普及,抗体检测已成为天疱疮临床诊断、病程监测的重要方法。新近临床研究提示,抗Dsg1、Dsg3抗体滴度与天疱疮病情活动程度间存在相关性,同时可监测病情的复发及指导临床用药。
中图分类号:
王麒钧, 朱海琴, 潘萌. 天疱疮主要自身抗体及其检测临床意义研究进展[J]. 诊断学理论与实践, 2022, 21(05): 638-643.
WANG Qijun, ZHU Haiqin, PAN Meng. Major autoantibodies in pemphigus: detection and clinical significance[J]. Journal of Diagnostics Concepts & Practice, 2022, 21(05): 638-643.
表1
临床常用抗体检测方法诊断天疱疮的灵敏度及特异度
检测方法 | 检测底物 | 疾病 | 灵敏度 | 特异度 |
---|---|---|---|---|
直接免疫荧光 | 皮肤样本 | PV/PF | 82%~91% | 98% |
间接免疫荧光 | 猴食道 | PV/PF | 81%~100% | 89%~100% |
鼠膀胱 | PNP | 74% | 99%~100% | |
酶联免疫吸附试验 | Dsg1 | PF | 96%~100% | 96%~100% |
Dsg3 | PV | 85%~100% | 96%~100% | |
Envoplakin | PNP | 63%~83% | 91%~98% | |
Periplakin | PNP | 60% | 无数据 | |
BIOCHIP | 猴食道 | PV/PF | 83%~100% | 89%~100% |
重组Dsg1 | PV/PF | 38%~90% | 99% | |
重组Dsg3 | PV | 87%~100% | 97%~100% |
[1] |
Hegazy S, Bouchouicha S, Khaled A, et al. IgA pemphigus showing IgA antibodies to desmoglein 1 and 3[J]. Dermatol Pract Concept, 2016, 6(4):31-33.
pmid: 27867744 |
[2] |
Lo AS, Mao X, Mukherjee EM, et al. Pathogenicity and epitope characteristics do not differ in IgG subclass-switched anti-desmoglein 3 IgG1 and IgG4 autoantibo-dies in pemphigus vulgaris[J]. PLoS One, 2016, 11(6):e0156800.
doi: 10.1371/journal.pone.0156800 URL |
[3] |
Yeoh SC, Byth-Wilson K, Murrell DF, et al. Pemphigus vulgaris disease activity: The role of antibodies to desmogleins and their isotype[J]. J Oral Pathol Med, 2019, 48(7):619-625.
doi: 10.1111/jop.12913 URL |
[4] |
Recke A, Konitzer S, Lemcke S, et al. The p. Arg435His variation of IgG3 with high affinity to FcRn is associated with susceptibility for pemphigus vulgaris-analysis of four different ethnic cohorts[J]. Front Immunol, 2018, 9:1788.
doi: 10.3389/fimmu.2018.01788 URL |
[5] |
Nagel A, Lang A, Engel D, et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3[J]. Clin Immunol, 2010, 134(3):320-330.
doi: 10.1016/j.clim.2009.11.006 pmid: 20015693 |
[6] | Schmitt T, Waschke J. Autoantibody-specific signalling in pemphigus[J]. Front Med (Lausanne), 2021, 8:701809. |
[7] |
Spindler V, Waschke J. Pemphigus-a disease of desmosome dysfunction caused by multiple mechanisms[J]. Front Immunol, 2018, 9:136.
doi: 10.3389/fimmu.2018.00136 pmid: 29449846 |
[8] |
Ishii K, Yoshida K, Stanley JR, et al. Pemphigus vulgaris and foliaceus IgG autoantibodies directly block hete-rophilic transinteraction between desmoglein and desmocollin[J]. J Invest Dermatol, 2020, 140(10):1919-1926.
doi: S0022-202X(20)30220-7 pmid: 32142800 |
[9] |
Schmitt T, Egu DT, Walter E, et al. Ca2+ signalling is critical for autoantibody-induced blistering of human epidermis in pemphigus[J]. Br J Dermatol, 2021, 185(3):595-604.
doi: 10.1111/bjd.20091 pmid: 33792909 |
[10] |
Yoshida K, Ishii K, Shimizu A, et al. Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering[J]. J Dermatol Sci, 2017, 85(3):197-207.
doi: S0923-1811(16)31058-1 pmid: 28024684 |
[11] |
Walter E, Vielmuth F, Wanuske MT, et al. Role of Dsg1- and Dsg3-mediated signaling in pemphigus autoantibody-induced loss of keratinocyte cohesion[J]. Front Immunol, 2019, 10:1128.
doi: 10.3389/fimmu.2019.01128 pmid: 31178865 |
[12] |
Radeva MY, Walter E, Stach RA, et al. ST18 enhances PV-IgG-Induced Loss of Keratinocyte Cohesion in Parallel to Increased ERK Activation[J]. Front Immunol, 2019, 10:770.
doi: 10.3389/fimmu.2019.00770 pmid: 31057535 |
[13] | Meltzanidou P, Patsatsi A, Kyriakou A, et al. Detection of IgG autoantibodies against desmocollin-3 in greek patients with pemphigus[J]. Acta Dermatovenerol Croat, 2019, 27(1):8-10. |
[14] |
Kalantari-Dehaghi M, Anhalt GJ, Camilleri MJ, et al. Pemphigus vulgaris autoantibody profiling by proteomic technique[J]. PLoS One, 2013, 8(3):e57587.
doi: 10.1371/journal.pone.0057587 URL |
[15] |
Chen J, Den Z, Koch PJ. Loss of desmocollin 3 in mice leads to epidermal blistering[J]. J Cell Sci, 2008, 121(Pt 17):2844-2849.
doi: 10.1242/jcs.031518 pmid: 18682494 |
[16] |
Spindler V, Heupel WM, Efthymiadis A, et al. Desmocollin 3-mediated binding is crucial for keratinocyte cohesion and is impaired in pemphigus[J]. J Biol Chem, 2009, 284(44):30556-30564.
doi: 10.1074/jbc.M109.024810 pmid: 19717567 |
[17] |
Maruta CW, Miyamoto D, Aoki V, et al. Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview[J]. An Bras Dermatol, 2019, 94(4):388-398.
doi: S0365-05962019000400388 pmid: 31644609 |
[18] |
Amber KT, Valdebran M, Grando SA. Non-desmoglein antibodies in patients with pemphigus vulgaris[J]. Front Immunol, 2018, 9:1190.
doi: 10.3389/fimmu.2018.01190 pmid: 29915578 |
[19] | Chernyavsky A, Patel KG, Grando SA. Mechanisms of synergy of autoantibodies to M3 muscarinic acetylcholine receptor and secretory pathway Ca2+/Mn2+-ATPase isoform 1 in patients with non-desmoglein pemphigus vulgaris[J]. Int Immunopharmacol, 2020,106149. |
[20] | 谢志敏, 沈旭成, 戴向农, 等. 非桥粒芯糖蛋白抗体在寻常型天疱疮中的作用机制[J]. 中国麻风皮肤病杂志, 2021, 37(5):324-327. |
Xie ZM, Shen XC, Dai XN, et al. Update of non-desmoglein IgG autoantibodies in the pathogenesis of pemphigus vulgaris[J]. China J Lepr Skin Dis, 2021, 37(5):324-327. | |
[21] | 潘萌, 郑捷. 寻常型天疱疮自身抗体检测及治疗方法的进展[J]. 中华皮肤科杂志, 2018, 51(1):5-9. |
Pan M, Zheng J. Advances in detection and treatment of autoantibodies in pemphigus vulgaris[J]. Chin J Dermatol, 2018, 51(1):5-9. | |
[22] |
Saschenbrecker S, Karl I, Komorowski L, et al. Serological diagnosis of autoimmune bullous skin diseases[J]. Front Immunol, 2019, 10:1974.
doi: 10.3389/fimmu.2019.01974 pmid: 31552014 |
[23] |
Zhao WL, Ishii K, Egami S, et al. Analysis of clinical characteristics, prognosis and antibody pathogenicity of pemphigus patients positive for anti-desmoglein IgG autoantibodies in remission: a retrospective cohort study[J]. J Eur Acad Dermatol Venereol, 2022, 36(2):271-278.
doi: 10.1111/jdv.17770 URL |
[24] |
Wang M, Li F, Wang X, et al. BIOCHIP mosaic for the diagnosis of autoimmune bullous diseases in Chinese patients[J]. Eur J Dermatol, 2020, 30(4):338-344.
doi: 10.1684/ejd.2020.3839 pmid: 32969793 |
[25] |
Fujio Y, Kojima K, Hashiguchi M, et al. Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid[J]. J Dermatol Sci, 2017, 85(3):208-215.
doi: S0923-1811(16)31021-0 pmid: 28012821 |
[26] |
Mai Y, Ujiie H, Higashi T, et al. Autoantibodies undetectable by chemiluminescent enzyme immunoassay require extended antigen-antibody reaction time for detection[J]. Br J Dermatol, 2019, 180(1):215-216.
doi: 10.1111/bjd.17121 pmid: 30171687 |
[27] |
Korgaonkar SA, Chougule DA, Khopkar US, et al. Quantitative estimation of antidesmoglein autoantibodies by ELISA in pemphigus patients and its correlation with disease activity[J]. Indian J Dermatol, 2021, 66(1):98-99.
doi: 10.4103/ijd.IJD_723_18 pmid: 33911304 |
[28] |
Russo I, de Siena FP, Saponeri A, et al. Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission[J]. Medicine (Baltimore), 2017, 96(46):e8801.
doi: 10.1097/MD.0000000000008801 URL |
[29] |
Abasq C, Mouquet H, Gilbert D, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus[J]. Arch Dermatol, 2009, 145(5):529-535.
doi: 10.1001/archdermatol.2009.9 pmid: 19451496 |
[30] | 金欣星, 李思哲, 左亚刚, 等. 8例缓解期高滴度血清抗体的天疱疮患者临床分析[J]. 中国医学科学院学报, 2021, 43(2):166-172. |
Jin XX, Li SZ, Zuo YG, et al. Clinical analysis of eight cases of pemphigus with high titers of anti-desmoglein antibodies in remission[J]. Acta Acad Med Sinicae, 2021, 43(2):166-172. | |
[31] |
Kamiya K, Aoyama Y, Shirafuji Y, et al. A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris[J]. J Dermatol Sci, 2013, 70(3):190-195.
doi: 10.1016/j.jdermsci.2013.02.011 pmid: 23602628 |
[32] | 朱海琴, 潘萌, 陈娅苑, 等. 天疱疮特异性抗体亚型与疾病活动的相关性研究[J]. 中华皮肤科杂志, 2011, 44(1):7-10. |
Zhu HQ, Pan M, Chen YY, et al. Correlation between disease activity and pemphigus-specific antibody subclasses in patients with pemphigus[J]. Chin J Dermatol, 2011, 44(1):7-10. | |
[33] | 来学民, 赵玉铭, 王雅坤. 天疱疮患者头发毛囊直接免疫荧光检测及其临床意义探讨[J]. 中国皮肤性病学杂志, 2015, 29(11):1134-1136. |
LAI Xuemin, ZHAO Yuming, WANG Yakun. The detection and clinical significance of direct immunofluorescence of antibodies in the follicles of patients with pemphigus[J]. Chin J Dermatovenereology, 2015, 29(11):1134-1136. | |
[34] |
Daneshpazhooh M, Zafarmand Sedigh V, et al. Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission[J]. J Am Acad Dermatol, 2016, 74(6):1160-1165.
doi: 10.1016/j.jaad.2015.10.051 pmid: 26896293 |
[35] |
Genovese G, Maronese CA, Casazza G, et al. Clinical and serological predictors of relapse in pemphigus: a study of 143 patients[J]. Clin Exp Dermatol, 2022, 47(1):98-106.
doi: 10.1111/ced.14854 URL |
[36] | Mignard C, Maho-Vaillant M, Golinski ML, et al. Factors associated with short-term relapse in patients with pem-phigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial[J]. JAMA Der-matol, 2020, 156(5):545-552. |
[1] | 张浩, 池慧慧, 苏禹同, 杨程德. 特发性炎性肌病自身抗体与临床表型间关联的研究进展[J]. 诊断学理论与实践, 2022, 21(03): 408-414. |
[2] | 关茵, 许飞, 田宗斌. 河南焦作地区2014年至2017年疑难交叉配血不合的处理及分析[J]. 诊断学理论与实践, 2019, 18(1): 86-88. |
[3] | 张莉莉, 朱洁. 神经系统自身免疫性疾病的抗体检测及临床意义[J]. 诊断学理论与实践, 2018, 17(04): 396-402. |
[4] | 周鑫昀, 沈立松, 潘秀军. 新型自身抗体及相关抗原在1型糖尿病诊治中的研究进展[J]. 诊断学理论与实践, 2018, 17(03): 352-356. |
[5] | 周桑, 沈茜, 秦永文. 肌钙蛋白I自身抗体在心肌梗死诊断中的临床意义[J]. 诊断学理论与实践, 2017, 16(01): 120-122. |
[6] | 林孝怡, 梁茜, 林琳, 丁秋兰, 王学锋, 王颖,. 抗膜突蛋白抗体在抗磷脂综合征中的初步研究[J]. 诊断学理论与实践, 2015, 14(01): 31-35. |
[7] | 叶廷军, 袁勤, 施新明, 樊绮诗,. 亚急性甲状腺炎患者的血清指标变化与细胞病理学特征[J]. 诊断学理论与实践, 2009, 8(04): 401-404. |
[8] | 李继强, 张洁,. 自身免疫性肝病相关抗体检测及其临床意义[J]. 诊断学理论与实践, 2006, 5(04): 298-300. |
[9] | 张华,陈华,王文菁. 自身抗体筛检隐匿型自身免疫性糖尿病的意义[J]. 诊断学理论与实践, 2005, 4(01): 62-64. |
[10] | 耿红莲,屠小卿,朱烨,陈军,顾鹏飞,范列英,仲人前. 冠心病患者血清中相关自身抗体的检测及临床意义[J]. 诊断学理论与实践, 2004, 3(05): 35-37. |
[11] | 贾秀娟,谢晓雁,张迪,周文中,刘优萍,郑升,杨键,罗敏. 胰岛素瘤相关蛋白-2自身抗体酶联免疫吸附测定方法的建立[J]. 诊断学理论与实践, 2003, 2(02): 30-32. |
[12] | 周智广. 特发性1型糖尿病的诊断[J]. 诊断学理论与实践, 2003, 2(02): 66-67. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||